"Company","Parent Company","Penalty Amount","Subtraction From Penalty","Penalty Amount Adjusted For Eliminating Multiple Counting","Penalty Year","Penalty Date","Offense Group","Primary Offense","Secondary Offense","Description","Level of Government","Action Type","Agency","Civil/Criminal","Prosecution Agreement","Court","Case ID","Private Litigation Case Title","Lawsuit Resolution","Facility State","City","Address","Zip","NAICS Code","NAICS Translation","HQ Country of Parent","HQ State of Parent","Ownership Structure","Parent Company Stock Ticker","Major Industry of Parent","Specific Industry of Parent","Info Source","Notes"
"Cypress Pharmaceutical Inc.","Currax Pharmaceuticals","$2,800,000","$0","$2,800,000","2012","20120328","healthcare-related offenses","off-label or unapproved promotion of medical products","","Mississippi-based Cypress Pharmaceutical Inc., its subsidiary Hawthorn Pharmaceuticals Inc. and its CEO, Max Draughn, have agreed to pay $2.8 million to resolve civil allegations under the False Claims Act, the Justice Department announced. The government alleged that between 2003 and 2009, Cypress, Hawthorn and Draughn were responsible for marketing three pharmaceutical products that were not approved as safe and effective by the Food and Drug Administration (FDA). The products were Hylira, a gel used for the treatment of dry skin, Zaclir, an acne treatment and Zacare, another acne treatment.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil","","","","","","","","","","","","USA","New Jersey","privately held","","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/mississippi-pharmaceutical-firm-and-ceo-pay-28-million-resolve-allegations-illegal-marketing",""
"PERNIX THERAPEUTICS, LLC","Currax Pharmaceuticals","$10,001","$0","$10,001","2019","20190318","employment-related offenses","benefit plan administrator violation","","Deficient Filer","federal","agency action","Employee Benefits Security Administration","civil","","","","","","New Jersey","","","-7960","","","USA","New Jersey","privately held","","pharmaceuticals","pharmaceuticals","https://enforcedata.dol.gov/views/data_summary.php","Company is plan administrator. Penalty amount reported in range of $10,001 to $50,000. "
"Pernix Therapeutics","Currax Pharmaceuticals","$800,000","$0","$800,000","2013","20131118","government-contracting-related offenses","False Claims Act and related","","The Louisiana Attorney General's Office announced that it had obtained a total of $88 million in settlements from 25 pharmaceutical companies to resolve allegations they overcharged the state's Medicaid program.","state","agency action","Louisiana Attorney General","civil","","","","","","Louisiana","","","","","","USA","New Jersey","privately held","","pharmaceuticals","pharmaceuticals","https://web.archive.org/web/20131206104321/http://www.ag.state.la.us/Article.aspx?articleID=788&catID=2",""
